Genkyotex Innovation SAS   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Paris France (2001)
Status: Acquired by Calliditas Therapeutics (2020)

Organization Overview

First Clinical Trial
2013
NCT02010242
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Genkyotex SA | Genkyotex Suisse SA

Active Ingredients

Drugs in Phase 3 Trials (1)

setanaxib (2 trials)

Drugs in Phase 2 Trials (2)

gkt137831 (3 trials)

procervix (1 trial)

Drugs in Phase 1 Trials (2)

gtl001 (1 trial)

imiquimod (aldara) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 2)

Atypical Squamous Cells of the Cervix (Phase 1)

Cholangitis (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 2)

Infections (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Papilloma (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5